Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Martin Bader

Johannes Auer

Stefan Lorenz

Stefan Seeber

Stefan Dengl

Roberto Falkenstein

Joerg Moelleken

Jens Fischer

Christian Schantz

Hubert Kettenberger

Ulrich Goepfert

Ulrich Kohnert

Monika Baehner

Maximiliane Koenig

Juergen Fingerle

Silke Mohl

Jean-Luc Mary

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-I-CS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Method for producing monomeric and multimeric molecules and uses thereof

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-ICS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.

TNFa-IL-17 bispecific antibodies

Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human tau(pS422) and an anti-blood brain barrier receptor/hapten bispecific antibody.

Humanized anti-tau(pS422) antibody brain shuttles and use thereof

The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies against human TWEAK and human IL17 and uses thereof

A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.

Tetranectin-apolipoprotein A-I, lipid particles containing it and its use

Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof.

Growing community of inventors

Penzberg, Germany

Martin Bader